The Estimated Annual Cost of Uterine Leiomyomata in the United States
By E. Cardozo, A. Clark, N. Banks, M. Henne, B. Stegmann, J. Segars. American Journal of Obstetrics and Gynecology, 2011
648 citations recorded by the source corpus.
Objective To estimate the total annual societal cost of uterine fibroids in the United States, based on direct and indirect costs, including associated obstetric complications. Study Design A systematic review of the literature was conducted to estimate the number of women seeking treatment for symptomatic fibroids annually, the costs of medical and surgical treatment, work lost and obstetric complications attributable to fibroids. Total annual costs were converted to 2010 U.S. dollars. A sensitivity analysis was performed. Results The estimated annual direct costs (surgery, hospital admissions, outpatient visits, medications) were $4.1 to $9.4 billion. Estimated lost work costs ranged from $1.55 to $17.2 billion annually. Obstetric outcomes attributed to fibroids resulted in a cost of $238 million to $7.76 billion annually. Uterine fibroids were estimated to cost the US $5.9 to $34.4 billion annually. Conclusions Obstetric complications associated with fibroids contributed significantly to their economic burden. Lost work costs may account for the largest proportion of societal costs due to fibroids.
Subfields: Obstetrics and Gynecology, Reproductive Medicine
View Paper: https://www.semanticscholar.org/paper/77e839529e335f0dbd76b7fba4af2abe58b92a9b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Obstetrics and Gynecology
In Reproductive Medicine
Citations in the corpus
- Uterine fibroid management: from the present to the future (2016, background): “There is no doubt that fibroids have a significant economic impact (Cardozo et al., 2012; Soliman et al., 2015), but the cost of therapy both to the health care system and women with fibroids must be balanced against the cost of untreated disease conditions, as well as the cost of ongoing or…”